Oramed Pharmaceuticals (ORMP) stock price, revenue, and financials

Oramed Pharmaceuticals market cap is $103.5 m, and annual revenue was $2.70 m in FY 2019
View Company

$103.5 M

ORMP Mkt cap, 15-Jan-2021

$674 K

Oramed Pharmaceuticals Revenue Q1, 2021
Oramed Pharmaceuticals Cash, 30-Nov-202014.9 M
Oramed Pharmaceuticals EV89.2 M

Oramed Pharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

641.0k2.5m2.4m2.7m

Cost of goods sold

490.0k187.0k90.0k

Gross profit

151.0k2.3m2.6m

Gross profit Margin, %

24%92%97%

Sales and marketing expense

284.9k

R&D expense

1.7m3.3m7.7m10.3m12.0m13.5m

General and administrative expense

1.2m2.6m2.5m2.8m4.1m3.7m

Operating expense total

3.2m5.9m10.2m13.0m16.1m17.2m

Depreciation and amortization

4.0k4.0k

EBIT

(2.9m)(5.9m)7.4m

Interest expense

138.0k

Interest income

13.1k225.0k168.0k792.0k903.0k1.1m

Pre tax profit

(3.3m)(5.7m)7.2m(9.6m)(10.1m)(12.7m)(14.1m)

Income tax expense

90.2k4.0k1.0k1.3m400.0k300.0k

Net Income

(3.3m)(5.7m)7.2m

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

125.0k163.0k(610.0k)611.0k(617.0k)611.0k604.0k617.0k674.0k666.0k682.0k674.0k674.0k681.0k674.0k

Cost of goods sold

187.0k86.0k35.0k55.0k

Gross profit

(797.0k)531.0k639.0k611.0k

Gross profit Margin, %

131%86%95%92%

R&D expense

184.0k710.6k249.8k392.6k749.0k835.6k1.3m1.7m3.1m2.3m2.7m4.2m4.3m3.1m3.9m2.0m3.3m1.9m5.8m

General and administrative expense

281.9k229.7k290.7k339.2k510.8k499.0k730.0k555.0k851.0k1.0m991.0k1.0m932.0k1.1m899.0k1.1m1.4m1.0m727.0k

Operating expense total

465.9k940.4k540.4k731.8k1.3m1.3m2.0m2.3m(2.8m)4.0m3.3m3.7m5.2m5.3m4.2m4.8m3.1m4.7m3.0m6.5m

EBIT

(465.9k)(940.4k)(540.4k)(731.8k)(1.3m)(1.3m)2.4m2.2m

EBIT margin, %

(393%)(349%)

Interest income

7.0k7.6k306.072.2k66.8k84.6k210.0k222.0k217.0k209.0k286.0k273.0k263.0k209.0k200.0k

Pre tax profit

(478.5k)(985.4k)(550.4k)(958.8k)(1.2m)(1.3m)2.2m(3.2m)2.0m(2.5m)(2.9m)(4.4m)(3.4m)(4.1m)3.7m2.3m

Income tax expense

(400.0k)300.0k

Net Income

(478.5k)(985.4k)(550.4k)(958.8k)(1.2m)(1.3m)(2.6m)2.0m3.7m2.3m

Oramed Pharmaceuticals Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.4m2.3m3.2m3.9m4.0m5.0m3.3m

Accounts Receivable

87.7k58.4k

Prepaid Expenses

2.3k90.1k127.0k198.0k159.0k574.0k1.0m

Current Assets

5.3m8.6m17.4m31.2m20.3m31.0m33.3m

PP&E

4.8k5.8k11.0k16.0k18.0k17.0k24.0k

Total Assets

5.3m8.7m26.4m42.8m38.7m47.4m34.7m

Accounts Payable

597.2k450.9k953.0k1.4m2.7m2.1m2.5m

Short-term debt

2.7m

Current Liabilities

644.4k498.2k1.5m3.6m5.2m4.6m5.3m

Long-term debt

9.7m

Non-Current Liabilities

872.4k31.2k37.0k13.0m14.3m11.7m10.0m

Total Debt

12.4m

Common Stock

80.1k95.2k138.0k157.0k163.0k207.0k208.0k

Additional Paid-in Capital

21.6m29.9m59.2m71.9m75.2m99.4m100.3m

Retained Earnings

(17.9m)(22.1m)(35.1m)(46.0m)(56.5m)(69.2m)(81.1m)

Total Equity

3.8m8.1m24.8m26.2m19.2m31.1m19.4m

Financial Leverage

1.4 x1.1 x1.1 x1.6 x2 x1.5 x1.8 x

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

1.5m1.8m1.3m5.5m2.0m1.1m1.4m3.3m2.5m6.7m1.1m1.9m3.2m3.3m2.3m1.5m1.7m1.3m3.3m3.7m3.9m3.2m5.9m9.3m14.9m

Accounts Receivable

86.0k46.7k135.4k76.0k439.8k333.7k73.1k267.1k27.0k2.0k

Prepaid Expenses

18.5k12.8k21.0k18.8k36.4k62.3k172.9k245.6k97.5k120.0k129.0k112.0k417.0k421.0k430.0k151.0k127.0k163.0k224.0k209.0k727.0k609.0k563.0k470.0k1.7m

Current Assets

3.9m3.1m2.5m6.8m5.9m4.8m8.0m23.7m16.0m24.5m18.3m15.2m26.0m25.1m30.5m29.8m26.3m19.1m21.1m23.6m29.7m30.7m29.5m41.3m36.0m

PP&E

11.3k7.8k2.1k2.5k1.9k5.7k8.8k12.2k13.5k15.0k13.0k12.0k11.0k17.0k15.0k16.0k17.0k17.0k18.0k17.0k23.0k27.0k25.0k22.0k409.0k

Total Assets

3.9m3.1m2.5m6.8m6.0m4.8m8.0m23.7m22.5m24.6m23.0m23.9m38.4m36.3m44.9m41.8m39.8m41.5m38.3m34.7m43.6m31.1m29.9m46.2m41.0m

Accounts Payable

357.3k534.9k308.6k287.3k422.1k398.8k621.3k302.6k447.8k795.0k570.0k768.0k829.0k646.0k2.2m2.4m2.5m2.6m2.2m3.1m3.0m1.8m2.4m1.4m2.8m

Short-term debt

46.0k32.0k32.0k138.0k

Current Liabilities

424.4k582.2k355.9k334.6k469.4k446.0k668.5k349.8k495.0k827.0k605.0k1.3m1.5m1.3m4.7m4.9m5.0m5.1m4.7m5.6m4.2m4.6m5.2m4.1m5.7m

Long-term debt

60.0k67.0k57.0k502.0k

Non-Current Liabilities

160.8k162.0k146.8k240.4k239.9k241.1k31.9k32.4k31.9k36.0k36.0k38.0k4.1m4.0m16.2m15.6m14.9m13.7m13.1m12.4m10.6m9.3m8.6m7.9m7.0m

Total Debt

106.0k99.0k89.0k640.0k

Total Liabilities

744.1k502.7k

Common Stock

70.1k70.2k70.4k86.5k86.7k86.7k95.4k117.3k119.5k129.0k129.0k138.0k157.0k157.0k158.0k159.0k159.0k170.0k171.0k172.0k207.0k209.0k214.0k279.0k286.0k

Additional Paid-in Capital

18.3m18.3m18.4m24.8m25.0m25.3m30.1m46.7m47.6m53.2m53.5m59.7m71.6m71.8m72.4m72.8m73.0m80.9m81.9m82.6m99.7m100.6m103.2m123.5m126.1m

Retained Earnings

(15.0m)(16.0m)(16.6m)(18.9m)(20.1m)(21.3m)(23.2m)(24.4m)(26.2m)(29.7m)(31.4m)(37.4m)(39.3m)(41.3m)(48.7m)(51.8m)(53.8m)(59.0m)(61.9m)(66.3m)(71.0m)(83.6m)(87.3m)(89.6m)(98.2m)

Total Equity

3.3m2.4m2.0m6.2m5.2m4.2m7.3m23.3m22.0m23.7m22.3m22.5m32.7m31.0m24.0m21.3m19.8m22.7m20.5m16.7m28.9m207.0k207.0k17.2m16.1m34.1m28.2m

Financial Leverage

1.2 x1.3 x1.3 x1.1 x1.1 x1.2 x1.1 x1 x1 x1 x1 x1.1 x1.2 x1.2 x1.9 x2 x2 x1.8 x1.9 x2.1 x1.5 x1.8 x1.9 x1.4 x1.5 x

Oramed Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.3m)(4.2m)(5.7m)(11.0m)(10.5m)(12.7m)(14.4m)

Depreciation and Amortization

14.7k5.4k6.0k4.0k4.0k5.0k6.0k8.0k

Accounts Payable

203.1k(146.2k)475.0k

Cash From Operating Activities

(2.3m)(3.4m)(4.1m)(4.9m)4.7m(5.8m)(14.7m)(12.9m)

Purchases of PP&E

(2.1k)(6.4k)(14.0k)(1.0k)(9.0k)(7.0k)(5.0k)(15.0k)

Cash From Investing Activities

1.8m(4.6m)(13.1m)(3.3m)(16.0m)4.3m(7.0m)11.3m

Cash From Financing Activities

3.5m5.8m16.6m9.7m12.0m1.6m22.7m

Net Change in Cash

2.9m(2.2m)(510.0k)1.5m694.0k62.0k1.0m(1.7m)

Income Taxes Paid

300.0k

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(478.5k)(1.5m)(2.0m)(958.8k)(2.2m)(3.4m)(1.1m)(2.2m)(4.1m)(1.9m)(3.5m)(2.4m)(4.2m)(6.2m)(2.6m)(5.8m)7.8m(2.5m)(5.4m)(9.8m)(4.3m)(8.0m)(12.1m)(2.5m)(6.2m)(8.5m)(5.6m)

Depreciation and Amortization

6.0k11.7k17.4k2.3k2.9k3.7k1.9k3.0k4.1k1.0k3.0k1.0k2.0k3.0k1.0k2.0k4.0k1.0k3.0k4.0k2.0k4.0k4.0k2.0k5.0k2.0k

Accounts Payable

(16.9k)140.9k(85.4k)(309.9k)(175.0k)(198.4k)170.3k(148.4k)(3.1k)

Cash From Operating Activities

(466.7k)(1.1m)(2.0m)(792.8k)(2.1m)(3.1m)(748.7k)(2.2m)(3.3m)(1.4m)(3.0m)(2.2m)77.0k(2.1m)1.5m(1.4m)(3.8m)(2.7m)(6.2m)(10.0m)(4.1m)(6.0m)(9.7m)(3.0m)(6.6m)(10.0m)(6.2m)

Purchases of PP&E

(2.1k)(2.1k)(4.7k)(4.9k)(9.4k)(11.9k)(2.0k)(2.0k)(2.0k)(2.0k)(9.0k)(2.0k)(5.0k)(3.0k)(3.0k)(8.0k)(8.0k)(14.0k)(3.0k)(3.0k)(3.0k)(313.0k)

Cash From Investing Activities

448.9k1.4m1.7m454.2k(1.8m)(1.6m)(162.2k)(13.3m)(13.2m)1.5m(2.5m)818.0k(11.9m)(9.7m)(3.4m)(1.3m)1.3m(5.1m)(351.0k)3.5m3.0m4.4m8.6m2.8m6.9m(6.3m)1.2m

Cash From Financing Activities

1.5m1.5m1.5m16.5m16.6m4.8m4.8m164.0k11.9m11.9m320.0k320.0k320.0k5.2m5.9m6.2m13.0k2.3m22.3m586.0k

Net Change in Cash

(17.7k)310.8k(213.5k)(2.4m)(3.3m)(901.5k)980.7k202.6k4.9m(660.0k)(1.3m)17.0k89.0k(1.6m)(2.5m)(2.2m)(2.7m)(674.0k)(296.0k)(1.1m)(1.6m)(1.0m)(158.0k)2.6m6.0m(4.4m)

Oramed Pharmaceuticals Ratios

USDQ1, 2012

Financial Leverage

1.2 x
View Oramed Pharmaceuticals profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more